

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **October 28, 2024**

**NEXGEL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-41173**

(Commission  
File Number)

**26-4042544**

(IRS Employer  
Identification No.)

**2150 Cabot Boulevard West, Suite B  
Langhorne, Pennsylvania**

(Address of principal executive offices)

**19067**

(Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001	NXGL	The Nasdaq Capital Market LLC
Warrants to Purchase Common Stock	NXGLW	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On October 28, 2024, NexGel, Inc. began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "**Exchange Act**"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

Exhibit No.	Description
99.1	<a href="#">NexGel, Inc. Investor Presentation, dated October 2024.</a>
104	Cover Page Interactive Data File (formatted as Inline XBRL)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 28, 2024

**NEXGEL, INC.**

By: /s/ Adam Levy  
Adam Levy  
Chief Executive Officer

---



# Investor Presentation

October 2024



NASDAQ: NXGL

## Forward-Looking Statement

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



NASDAQ: NXGL

## NEXGEL – Who We Are and What We Do

After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products.

We invested in our in-house converting and packaging capabilities to better meet our customer's evolving needs.

These strategic growth opportunities reflect our dedication to pioneering advancements across various domains, delivering great value to our customers and stakeholders.

**Agreements with Multi-Billion Dollar Corporations**



abbvie



**Medtronic**



NASDAQ: NXGL

3

## Multiple Products & Applications for Nexgel's Technology



NASDAQ: NXGL

4

# Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA

*Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments*

1 of 2 manufacturing facilities in North America that can produce state-of-the-art hydrogel transdermal products  
– successfully used 200+ different active ingredient combinations to date



16,500-square-ft GMP  
13,500-square-ft manufacturing space

3,000-square-ft office space

>1.4 Billion square inches of product per year is total capacity

Sufficient capacity across healthcare and consumer divisions



NASDAQ: NXGL

Electron Beam Accelerator eliminates the need for harmful chemicals in hydrogel production

High barrier to entry for new facilities (2+ yrs to go live)

Stringent compliance requirements

Technical expertise needed to operate

5

## Converting and Packaging Facility

*50% ownership in converting and packaging business in Granbury, Texas*

- Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts
- Increased square footage and installed cutting-edge automated machinery in our clean room facilities to support anticipated growth
- CG Labs converting and packaging division is one of NEXGEL's largest customers



NASDAQ: NXGL





# Hydrogels for Consumer and Medical Applications

- Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers
- Gentle formulation & strong adhesion properties eliminates many problems with existing transdermal devices & dermal interfaces such as:
  - Deterioration of skin integrity
  - Skin allergies
  - Skin irritation
  - Discomfort
  - Skin tears
  - Removal of dermis
  - Pain

*All of these contribute to increased risk of infection and overall patient dissatisfaction*



NASDAQ: NXGL

7

## Current Medical Device Pipeline

Addressing the importance of skin integrity and overall skincare with a medical device



NASDAQ: NXGL

# Medical Device Pipeline: Drug Delivery

## Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology

Drug Delivery: Diclofenac Patch


To treat short-term pain due to preclinical sprains and bruises

Drug Delivery: Apremilast Patch

To treat autoimmune conditions, such as arthritis and psoriasis

- Promising pre-clinical human results (12 patients)
- Proof-of-concept study completed, validating the potential value of our hydrogel technology for pain indications (arthritis, joint pain, etc.)
- Compared to the current market, NEXGEL's product demonstrated enhanced efficacy (faster-acting, longer lasting, with no mess)

Comparative In-Vitro<sup>1</sup> Human Skin Permeation of Diclofenac Sodium from NEXGEL Patch After 8 Hours



1. In-vitro skin permeation performed using full thickness derma to med human cadaver skin; 250 microns thick in Franz cells (3.65 ml volume with 0.95 cm2 surface area) at 37°C. Receptor compartment contained pH 7.4 PBS. 4 cells per formulation sample. Sampling times at 2, 4, and 8 hours. Analysis by HPLC.

2. Skin samples were removed from Franz cell after 8 hours permeation experiment and extracted in ethanol for 12 hours at 37°C. Analysis by HPLC.



NASDAQ: NXGL

9

# Medical Device Pipeline – Surgical Drape

*NEXDrape* - A "skin friendly" solution for the surgical drape 510(k) market; providing consistent adhesion; greater skin integrity; comfortable removal post surgery; decreased skin irritation.



VS



*IRB study* in accordance with FDA designed to measure the efficacy of NEXGEL's hydrogel during laser hair removal in eliminating harmful particles or plume during treatments.

*Appointed Kip Crecca*, current VP of North America Sales at MicroSurgical Technology, to Scientific Advisory Board to advance medical device and healthcare programs.

*Other potential applications:*

Negative pressure, colostomy bags, skin scaffolds, antimicrobial adhesive strips



NASDAQ: NXGL

10

# Consumer Health & Beauty

Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications



NASDAQ: NXGL

## NEXGEL Branded Products

NOW PARABEN-FREE



NASDAQ: NXGL



66

"A little hexagon miracle! I felt immediate relief. I was astounded and will be a customer for life!"

~ Medagel Customer



# M&A Strategy: Consumer Brand Acquisition

## Kenkoderm Skincare Line

- Acquisition completed in December 2023
- Complimentary line of alternative psoriasis treatments
- Profitable (ttm) and immediately accretive
- 6 SKUs sold primarily DTC with significant portion of revenue derived from subscription bundles




Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins

New marketing strategies and distribution channels in place to reach a wider consumer base

NASDAQ: NXGL

## Silly George Beauty Brand

- Acquisition completed in May 2024
- Specialty eye and eyelash consumer product line
- Annual run-rate of \$2mm when purchased, now \$5mm
- Currently DTC and on Amazon
- Social media following: 89,000 Facebook and 86,000 Instagram followers + 254,000 active customer emails



13

## Cintas Corporation

*Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America*

- Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors including hospitality and public service.
- This wound care solution will be available for employees of their customers.
- Partnership is significant for associated revenue, but also brand recognition among this consumer demographic.
- First order of SilverSeal is expected to be delivered during fourth quarter of 2024.



NASDAQ: NXGL

14

# STADA Arzneimittel AG

*Partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio*

- In 2022, STADA generated revenue of EUR 3.8 billion and EBITDA of EUR 885 million.
- STADA already focuses on consumer healthcare products, generics and specialty pharm, selling products in approximately 120 countries across the world and this partnership will provide a path into North America.
- Mutually beneficial partnership to distribute and commercialize STADA consumer health OTC products in North America in 2024.
- First product to be distributed and commercialized is Europe's #1 selling DAO enzyme supplement, Histasolv, a novel treatment for histamine food intolerance, in North America.
- This supplement is generating well over \$10 million in annualized revenue in Europe today.



NASDAQ: NXGL

15

# AbbVie (NYSE: ABBV)

*CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite*

- Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for \$550 million in December 2021
- Leveraging NEXGEL's proprietary hydrogel technology, the gel pads are an important component and must be used FOR ALL body contouring device treatments
- In Q1, received a non-refundable \$176,000 deposit from Abbvie against their first order
- It is expected the Resonic technology will be rolled out by the end of 2024




NASDAQ: NXGL

**THE WALL STREET JOURNAL.**  
**Allergan Aesthetics**  
**Completes \$550M**  
**Acquisition of Soliton**  
December 22, 2021



## Revenue Growth / Record for Q3 '24



NASDAQ: NXGL

\* Preliminary record third quarter 2024 revenue

- Growth in 2H of 2024 has exceeded expectations for both contract manufacturing and consumer products
- Q3 to Q4 sequential growth is expected
- Increased contract manufacturing revenue is primarily due to new customer relationship with large global corporations
- Brands are also experiencing significant growth, particularly Silly George with strong customer acquisition and repurchase rates
- Projections do not yet include any revenue from AbbVie

***2H growth moves company closer to positive cash flow from operations***

17

## Contact Us

Investor Relations:  
KCSA Strategic Communications  
Valter Pinto, Managing Director  
PH: (212) 896-1254  
[NEXGEL@KCSA.com](mailto:NEXGEL@KCSA.com)



NASDAQ: NXGL

18